4005-06-5

Basic information

• Product Name: 2-(2-METHYL-4-OXO-4 H-QUINAZOLIN-3-YL)-BENZOIC ACID
• Synonyms: CHEMBRDG-BB 5877923;2-(2-METHYL-4-OXO-4 H-QUINAZOLIN-3-YL)-BENZOIC ACID;2-(2-METHYL-4-OXOQUINAZOLIN-3(4H)-YL)BENZOIC ACID;2-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzoic acid(SALTDATA: FREE)
• CAS NO: 4005-06-5
• Molecular Formula: C₁₆H₁₂N₂O₃
• Molecular Weight: 280.28
• Mol File: 4005-06-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 495°C at 760 mmHg
• Flash Point: 253.2°C
• Appearance: /
• Density: 1.32g/cm³
• Vapor Pressure: 1.29E-10mmHg at 25°C
• Refractive Index: 1.66
• CAS DataBase Reference: 2-(2-METHYL-4-OXO-4 H-QUINAZOLIN-3-YL)-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-METHYL-4-OXO-4 H-QUINAZOLIN-3-YL)-BENZOIC ACID(4005-06-5)
• EPA Substance Registry System: 2-(2-METHYL-4-OXO-4 H-QUINAZOLIN-3-YL)-BENZOIC ACID(4005-06-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 4005-06-5(Hazardous Substances Data)

Usage

Class

Quinazoline derivatives

Structural Relation

Quinazolinone

Pharmacological Properties

Potential antineoplastic agent

Cytotoxic Effects

May exhibit cytotoxic effects on cancer cells

Anti-inflammatory Properties

Suggested by research

Analgesic Properties

Suggested by research

Enzyme Inhibition Potential

Indicated by quinazoline structure

Therapeutic Agent Development

Candidate for the development of new therapeutic agents

Further Exploration

Needed to fully understand its pharmaceutical and medicinal potential

InChI:InChI=1/C16H12N2O3/c1-10-17-13-8-4-2-6-11(13)15(19)18(10)14-9-5-3-7-12(14)16(20)21/h2-9H,1H3,(H,20,21)

Upstream product

• 2006-80-6 2-(2-methyl-4-oxo-4H-quinazoline-3-yl)benzoic acid methyl ester 
• 89-52-1 o-acetylamino-benzoic acid 
• 525-76-8 2-methyl-4-oxo-3,1-benzoxazine 
• 118-92-3 anthranilic acid 
• 134-20-3 2-carbomethoxyaniline 
• 5416-80-8 2-methyl-1H-indole-3-carbaldehyde 

Downstream Products

• 612-34-0 N-anthraniloyl-anthranilic acid 
• 118-92-3 anthranilic acid 
• 882039-02-3 2-(2-formyl-4-oxo-4H-quinazolin-3-yl)-benzoic acid 
• 134793-86-5 5-[(Z)-Phenylimino]-5,6-dihydro-7,12a-diaza-benzo[a]anthracen-12-one 
• 134794-02-8 5-[(Z)-m-Tolylimino]-5,6-dihydro-7,12a-diaza-benzo[a]anthracen-12-one 
• 134794-01-7 5-[(Z)-3-Chloro-phenylimino]-5,6-dihydro-7,12a-diaza-benzo[a]anthracen-12-one 
• 134793-98-9 5-[(Z)-4-Chloro-phenylimino]-5,6-dihydro-7,12a-diaza-benzo[a]anthracen-12-one 
• 134794-00-6 5-[(Z)-3-Methoxy-phenylimino]-5,6-dihydro-7,12a-diaza-benzo[a]anthracen-12-one 
• 134793-85-4 6-Phenylaminomethyl-6H-7,12a-diaza-benzo[a]anthracene-5,12-dione 
• 134793-93-4 6-(m-Tolylamino-methyl)-6H-7,12a-diaza-benzo[a]anthracene-5,12-dione 
• 134793-99-0 5-[(Z)-3-Nitro-phenylimino]-5,6-dihydro-7,12a-diaza-benzo[a]anthracen-12-one 
• 134793-92-3 6-[(3-Chloro-phenylamino)-methyl]-6H-7,12a-diaza-benzo[a]anthracene-5,12-dione 
• 134793-89-8 6-[(4-Chloro-phenylamino)-methyl]-6H-7,12a-diaza-benzo[a]anthracene-5,12-dione 
• 134793-91-2 6-[(4-Methoxy-phenylamino)-methyl]-6H-7,12a-diaza-benzo[a]anthracene-5,12-dione 

Relevant articles and documents

Semi-synthesis and structural elucidation of brevicanines A–D, four new C19-diterpenoid alkaloids with rotameric phenomenon from Aconitum brevicalcaratum

Four new C19-diterpenoid alkaloids brevicanines A–D (1–4) with rotameric phenomenon were isolated from Aconitum brevicalcaratum. They all possessed an unusual axial chiral phenyl-quinazoline side chain and their structures were elucidated by extensive spectroscopic analysis and chemical methods. Meanwhile, brevicanines A and B were semi-synthesized from their parent compound scaconine to further confirm their structures. Variable-temperature NMR spectroscopy was also used to investigate the atropisomers of brevicanine A, in which two sets of signals in 1H NMR spectra were observed at room temperature and coalesced over 140 °C. It's the first time to determine the atropisomeric preference of diterpenoid alkaloids.

Synthesis and evaluation of new 4-oxoquinazolin-3(4H)-yl)benzoic acid and benzamide derivatives as potent antibacterial agents effective against multidrug resistant Staphylococcus aureus

Treatment of nosocomial and community acquired Staphylococcus aureus infections has become more challenging due to the egression of multi-drug resistance. This has spurred the need for rapid development of new therapeutic agents which can effectively negate the resistance mechanisms. In our current work, several new 4-oxoquinazolin-3(4H)-yl)benzoic acid and benzamide derivatives were synthesized and examined for their antimicrobial activity against ESKAP pathogen panel and pathogenic mycobacteria. In the primary screening, compounds 4a, 4b, 6′a, 6′b, 6′h, 6′i and 6′j were found to demonstrate selective and potent inhibitory activity against Staphylococcus aureus (MICs = 0.25–0.5 μg/mL). When tested against Vero cells, all the compounds were found to be non toxic possessing favourable selectivity index (SI > 10), which encouraged us for carrying out further studies. Compound 6′a (SI > 40) was tested against a number of multiple clinical strains of multi-drug resistant S. aureus and was found to exhibit potent activity, irrespective of the resistant status of the strain. Besides, compound 6′a also exhibited concentration dependent bactericidal activity and synergized with the FDA approved drugs tested. The interesting results obtained suggest the potential utility of the newly synthesized compounds for treatment of multidrug resistant S. aureus infections.

Formation of tryptanthrin compounds upon Oxone-induced dimerization of indole-3-carbaldehydes

Tryptanthrin is a natural product with numerous important pharmacological properties. Tryptanthrin and its analogs are commonly prepared by condensation of isatoic anhydride and isatin. In this Letter we investigate the formation of tryptanthrin derivatives upon Oxone-induced oxidative dimerization of indole-3-carbaldehydes.